VMT-𝛼-NET

Early results support α-PRRT as a potential first- or second-line therapeutic option. Ongoing phase III trials will be critical to confirm its long-term safety, survival outcomes, and role in routine clinical practice.

P1, N=20, Active, not recruiting, Yusuf Menda | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Sep 2025 --> Apr 2026 | Enrolling by invitation --> Active, not recruiting

Imaging with [203Pb]Pb-VMT-α-NET followed by a single dose of [212Pb]Pb-VMT-α-NET appears to be well tolerated with promising efficacy, even in a heterogenous and heavily pretreated patient population. Further studies are warranted to examine tolerability and efficacy over multiple treatment cycles in larger patient populations.

It also provides insight into the use of proliferating cell nuclear antigen (PCNA) inhibitors in combination with therapeutics in aggressive/metastatic PPGL. Through a comprehensive review of the latest developments and clinical practice, this review aims to guide healthcare professionals in improving the diagnostic accuracy and therapeutic efficacy of PPGL.

P1/2, N=280, Recruiting, Perspective Therapeutics | N=52 --> 280 | Trial completion date: Jan 2028 --> Dec 2029 | Trial primary completion date: Sep 2026 --> Nov 2029

As Pb-203 presents an accurate diagnostic surrogate to Pb-212, imaging with Pb-203-labelled peptides can be an important prerequisite to assess the feasibility of TAT with Pb-212-labelled agents. Here, we present the imaging data of a patient with metastatic NET with Pb-203 VMT-α-NET, a somatostatin receptor targeting agent, and demonstrate the matching distribution of Pb-203 VMT-α-NET with Ga-68 DOTANOC.

P1/2, N=53, Not yet recruiting, National Cancer Institute (NCI)

P1, N=24, Active, not recruiting, David Bushnell | Recruiting --> Active, not recruiting

P1, N=24, Recruiting, David Bushnell

P1/2, N=52, Not yet recruiting, Viewpoint Molecular Targeting